Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants with NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
- Conditions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 87
- Registration Number
- NCT06703346
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
- Conditions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Adaptimmune
- Registration Number
- NCT06617572
- Locations
- 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸Mayo Florida, Jacksonville, Florida, United States
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 7
- Registration Number
- NCT06048705
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 7
- Registration Number
- NCT05993299
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 5
- Registration Number
- NCT05943990
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
SPEARHEAD-3 Pediatric Study
- Conditions
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 20
- Registration Number
- NCT05642455
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 66
- Registration Number
- NCT05601752
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Madrid, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 3
- Registration Number
- NCT04752358
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸University Of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University School of Medicine- Siteman Cancer Center, Saint Louis, Missouri, United States
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 12
- Registration Number
- NCT04526509
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Adaptimmune
- Registration Number
- NCT04408898
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸Providence Cancer Institute Franz Head and Neck Clinic, Portland, Oregon, United States